Target Information

Target General Infomation
Target ID
T86836
Former ID
TTDI01911
Target Name
Human DNA
Target Type
Successful
Disease Acute myeloid leukemia; Grade IV malignant glioma [ICD9:205, 191; ICD10: C92.0, C71]
Breast cancer [ICD9: 174, 175; ICD10: C50]
Brain cancer [ICD9: 191, 225.0; ICD10: C71, D33]
Colorectal cancer [ICD9: 153, 154; ICD10: C18-C21]
Cancer [ICD9: 140-229; ICD10: C00-C96]
Grade IV astrocytoma [ICD9: 191; ICD10: C71]
Gastric cancer [ICD9: 151; ICD10: C16]
Human immunodeficiency virus infection [ICD9: 279.3; ICD10: B20-B26]
Head and neck cancer [ICD9: 140-149, 140-229; ICD10: C07-C14, C32-C33]
Influenza A virus H5N1 [ICD9: 487, 488; ICD10: J10, J11]
Influenza A virus H1N1; Influenza A virus H5N1 [ICD9: 487, 488; ICD10: J10, J11]
Liver cancer [ICD9: 140-229, 155, 203.0; ICD10: C22]
Leukemia [ICD9: 208.9; ICD10: C90-C95]
Metastatic pancreatic [ICD10: C25.9]
Multiple myeloma [ICD9: 203; ICD10: C90]
Myeloproliferative disease [ICD9: 205.1, 238.4, 289.89, 289.9; ICD10: D47.1]
Malaria [ICD10: B54]
Myelodysplastic syndrome [ICD9: 238.7; ICD10: D46]
Mycobacterium tuberculosis infection [ICD10: A15-A19]
Non-invasive bladder cancer [ICD9: 188; ICD10: C67]
Ovarian cancer [ICD9: 183; ICD10: C56]
Prostate cancer [ICD9: 185; ICD10: C61]
Soft tissue sarcoma [ICD9: 171; ICD10: C00-D49]
Solid tumours [ICD9: 140-199, 210-229; ICD10: C00-D48]
Skin disease [ICD10: L00-L99]
Unspecified [ICD code not available]
Drugs and Mode of Action
Drug(s) Bendamustine hydrochloride Drug Info Approved Leukemia [1]
Busulfan Drug Info Approved Myeloproliferative disease [2], [3]
Carboplatin Drug Info Approved Ovarian cancer [4], [5]
Carmustine Drug Info Approved Brain cancer [6], [7]
Cisplatin Drug Info Approved Cancer [8], [9]
Cyclophosphamide Drug Info Approved Cancer [10], [11]
Decitabine Drug Info Approved Myelodysplastic syndrome [12], [13], [14]
DTI-015 Drug Info Approved Liver cancer [15]
Ifosfamide Drug Info Approved Cancer [16], [17]
Melphalan Drug Info Approved Multiple myeloma [18], [19]
Oxaliplatin Drug Info Approved Colorectal cancer [20], [21]
Temozolomide Drug Info Approved Grade IV astrocytoma [22], [23]
Dicycloplatin Drug Info Registered Prostate cancer [24]
Apaziquone Drug Info Phase 3 Non-invasive bladder cancer [25]
Laromustine Drug Info Phase 3 Solid tumours [26]
Lurbinectedin Drug Info Phase 3 Leukemia [27]
Pafuramidine Drug Info Phase 3 Malaria [28]
Taxol/Paraplatin/Herceptin Drug Info Phase 3 Breast cancer [29]
13-DEOXYADRIAMYCIN HYDROCHLORIDE Drug Info Phase 2 Solid tumours [30]
CGC-11047 Drug Info Phase 2 Prostate cancer [31]
CO-101 Drug Info Phase 2 Metastatic pancreatic [32]
CYSTEMUSTINE Drug Info Phase 2 Solid tumours [33]
DM-CHOC-PEN Drug Info Phase 2 Brain cancer [34]
FAD-104 Drug Info Phase 2 Solid tumours [35]
JM216 Drug Info Phase 2 Solid tumours [36]
LADIRUBICIN Drug Info Phase 2 Breast cancer [37]
NDDP Drug Info Phase 2 Solid tumours [38]
NHS-IL2-LT Drug Info Phase 2 Solid tumours [39]
PM-00104 Drug Info Phase 2 Solid tumours [40]
TETRAPLATIN TETRANITRATE Drug Info Phase 2 Cancer [41]
TH-302 Drug Info Phase 2 Soft tissue sarcoma [42], [43]
TROXACITABINE Drug Info Phase 2 Solid tumours [44]
BN-2629 Drug Info Phase 1/2 Solid tumours [45]
GTU-TB vaccine Drug Info Phase 1/2 Mycobacterium tuberculosis infection [46]
MBO7133 Drug Info Phase 1/2 Liver cancer [47]
Melphalan flufenamide Drug Info Phase 1/2 Ovarian cancer [48]
SECTA belomycin Drug Info Phase 1/2 Solid tumours [49]
VAL-083 Drug Info Phase 1/2 Acute myeloid leukemia; Grade IV malignant glioma [50]
5-FP Drug Info Phase 1 Solid tumours [51]
BIZELESIN Drug Info Phase 1 Skin disease [52]
DABIS MALEATE Drug Info Phase 1 Solid tumours [53]
FFC-14A Drug Info Phase 1 Solid tumours [54]
GALAMUSTINE HYDROCHLORIDE Drug Info Phase 1 Solid tumours [55]
Gemcitabine prodrug Drug Info Phase 1 Cancer [56], [57]
INO-3401 Drug Info Phase 1 Influenza A virus H5N1 [58]
INO-3510 Drug Info Phase 1 Influenza A virus H1N1; Influenza A virus H5N1 [58]
LY-2334737 Drug Info Phase 1 Solid tumours [56]
NC-4016 Drug Info Phase 1 Cancer [59]
PENCLOMEDINE Drug Info Phase 1 Solid tumours [60]
Pennvax-B Drug Info Phase 1 Human immunodeficiency virus infection [61]
Pennvax-G Drug Info Phase 1 Human immunodeficiency virus infection [62]
RH 1 Drug Info Phase 1 Unspecified [63]
T-0128 Drug Info Phase 1 Solid tumours [64]
Thiarabine Drug Info Phase 1 Solid tumours [65]
ARANOSE Drug Info Discontinued in Phase 3 Cancer [66]
KW-2149 Drug Info Discontinued in Phase 3 Solid tumours [67]
ADOZELESIN Drug Info Discontinued in Phase 2 Solid tumours [68]
AP-5346 Drug Info Discontinued in Phase 2 Head and neck cancer [69]
BBR-3438 Drug Info Discontinued in Phase 2 Gastric cancer [70]
BISNAFIDE MESILATE Drug Info Discontinued in Phase 2 Solid tumours [71]
CARZELESIN Drug Info Discontinued in Phase 2 Solid tumours [72]
Glufosfamide Drug Info Discontinued in Phase 2 Ovarian cancer [73]
NB-506 Drug Info Discontinued in Phase 2 Solid tumours [74]
PIBROZELESIN HYDROCHLORIDE Drug Info Discontinued in Phase 2 Solid tumours [75]
Tallimustine Drug Info Discontinued in Phase 2 Solid tumours [76]
TOPIXANTRONE HYDROCHLORIDE Drug Info Discontinued in Phase 2 Gastric cancer [77]
Clomet Drug Info Discontinued in Phase 1 Solid tumours [78]
FK-973 Drug Info Discontinued in Phase 1 Solid tumours [79]
PLD-147 Drug Info Discontinued in Phase 1 Solid tumours [80]
RB-6145 Drug Info Discontinued in Phase 1 Solid tumours [81]
S-23906-1 Drug Info Discontinued in Phase 1 Solid tumours [82]
SR-271425 Drug Info Discontinued in Phase 1 Solid tumours [83]
SW-33377 Drug Info Discontinued in Phase 1 Solid tumours [84]
ZD-2767 Drug Info Discontinued in Phase 1 Solid tumours [85]
BW-A502U Drug Info Terminated Solid tumours [86]
Doxorubicin-CEA conjugate Drug Info Terminated Breast cancer [87]
Modulator 13-DEOXYADRIAMYCIN HYDROCHLORIDE Drug Info [88]
Apaziquone Drug Info
Azathioprine Delayed-Release minitablets Drug Info
Bendamustine hydrochloride Drug Info [1]
Busulfan Drug Info
Carboplatin Drug Info
Carmustine Drug Info [15]
CGC-11047 Drug Info [89]
Cisplatin Drug Info
Cyclophosphamide Drug Info
Decitabine Drug Info [12]
DM-CHOC-PEN Drug Info [90]
Doxorubicin-CEA conjugate Drug Info [91]
doxorubicin-LL2 conjugate, Immunomedics Drug Info [92]
doxorubicin-peptide-PEG conjugate, Watson Drug Info [92]
Glufosfamide Drug Info
Ifosfamide Drug Info
JM216 Drug Info [88]
LY-2334737 Drug Info [93]
Melphalan Drug Info
melphalan intravenous Drug Info [92]
NHS-IL2-LT Drug Info [88]
Oxaliplatin Drug Info
Pafuramidine Drug Info
PENCLOMEDINE Drug Info
PM-00104 Drug Info [94]
RH 1 Drug Info
Tallimustine Drug Info
Temozolomide Drug Info [91]
TH-302 Drug Info
VAL-083 Drug Info [95]
Binder 5-FP Drug Info [96]
ADOZELESIN Drug Info [97]
AMBAZONE Drug Info [98]
ARANOSE Drug Info [99]
BBR-3438 Drug Info [100]
BN-2629 Drug Info [101]
BW-A502U Drug Info [102]
CARZELESIN Drug Info [103]
CYSTEMUSTINE Drug Info [104]
DABIS MALEATE Drug Info [105]
DTI-015 Drug Info [15]
FAD-104 Drug Info [106]
FFC-14A Drug Info [107]
FK-973 Drug Info [108]
KW-2149 Drug Info [109]
LADIRUBICIN Drug Info [110]
Laromustine Drug Info [111]
MBO7133 Drug Info [112]
Melphalan flufenamide Drug Info [113]
NDDP Drug Info [114]
PIBROZELESIN HYDROCHLORIDE Drug Info [115]
PLD-147 Drug Info [116]
RB-6145 Drug Info [117]
S-23906-1 Drug Info [118]
SECTA belomycin Drug Info [119]
SR-271425 Drug Info [120]
SW-33377 Drug Info [121]
Taxol/Paraplatin/Herceptin Drug Info [29]
TETRAPLATIN TETRANITRATE Drug Info [122]
TROXACITABINE Drug Info [123]
ZD-2767 Drug Info [124]
Inhibitor AP-5346 Drug Info [125]
BISNAFIDE MESILATE Drug Info [126]
BIZELESIN Drug Info [97]
Clomet Drug Info [127]
CO-101 Drug Info [128]
Dicycloplatin Drug Info [129]
Gemcitabine prodrug Drug Info [128]
Lurbinectedin Drug Info [130]
NB-506 Drug Info [131]
NC-4016 Drug Info [132]
T-0128 Drug Info [133]
Thiarabine Drug Info [134]
TOPIXANTRONE HYDROCHLORIDE Drug Info [135]
Antagonist GALAMUSTINE HYDROCHLORIDE Drug Info [136]
References
REF 12008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
REF 2FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020954.
REF 3(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7136).
REF 4FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 076039.
REF 5(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7624).
REF 6FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 017422.
REF 7(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6800).
REF 8Using the zebrafish lateral line to screen for ototoxicity. J Assoc Res Otolaryngol. 2008 Jun;9(2):178-90. Epub 2008 Apr 12.
REF 9(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5343).
REF 10Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54.
REF 11(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7154).
REF 122006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
REF 13(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6805).
REF 14Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
REF 15Carmustine-induced toxicity, DNA crosslinking and O6-methylguanine-DNA methyltransferase activity in two human lung cancer cell lines. Eur J Cancer. 1991;27(12):1658-62.
REF 16FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 076078.
REF 17(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7201).
REF 18FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 014691.
REF 19(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7620).
REF 20The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer. Gan To Kagaku Ryoho. 2009 May;36(5):797-801.
REF 21(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7433).
REF 22Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20.
REF 23(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7301).
REF 24Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031375)
REF 25Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000838)
REF 26ClinicalTrials.gov (NCT00112554) Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia. U.S. National Institutes of Health.
REF 27ClinicalTrials.gov (NCT02421588) Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients. U.S. National Institutes of Health.
REF 28ClinicalTrials.gov (NCT00302341) DB289 Versus TMP-SMX for the Treatment of Acute Pneumocystis Jiroveci Pneumonia (PCP). U.S. National Institutes of Health.
REF 29Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2006 Jun 20;24(18):2786-92.
REF 30ClinicalTrials.gov (NCT00123877) Study of GPX-100 in the Treatment of Metastatic Breast Cancer. U.S. National Institutes of Health.
REF 31ClinicalTrials.gov (NCT00585416) Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer. U.S. National Institutes of Health.
REF 32ClinicalTrials.gov (NCT01233375) Study to Evaluate Efficacy of CO-1.01 as Second Line Therapy for Gemcitabine-Refractory Stage IV Pancreatic Adenocarcinoma. U.S. National Institutes of Health.
REF 33Results of a phase II trial with second-line cystemustine at 60 mg/m2 in advanced soft tissue sarcoma: a trial of the EORTC Early Clinical Studies Group. Eur J Cancer. 1998 Feb;34(3):422-3.
REF 34Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029242)
REF 35Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000888)
REF 36Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer. J Clin Oncol. 1999 Dec;17(12):3822-7.
REF 37Phase I and pharmacokinetic studies of PNU-159548, a novel alkycycline, administered intravenously to patients with advanced solid tumours. Eur J Cancer. 2002 Dec;38(18):2407-15.
REF 38ClinicalTrials.gov (NCT00004033) Liposomal-Cisplatin Analogue (L-NDDP) in Treating Patients With Malignant Pleural Mesothelioma. U.S. National Institutes of Health.
REF 39Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026542)
REF 40ClinicalTrials.gov (NCT00900562) Clinical Trial of PM00104 (Zalypsis) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy. U.S. National Institutes of Health.
REF 41ClinicalTrials.gov (NCT00014547) BBR 3464 in Treating Patients With Metastatic Small Cell Lung Cancer That Has Not Responded to Previous Treatment. U.S. National Institutes of Health.
REF 42ClinicalTrials.gov (NCT01403610) Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab. U.S. National Institutes of Health.
REF 43(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8695).
REF 44ClinicalTrials.gov (NCT00129948) Study for Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML). U.S. National Institutes of Health.
REF 45ClinicalTrials.gov (NCT02034227) Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia. U.S. National Institutes of Health.
REF 46Clinical pipeline report, company report or official report of FIT Biotech.
REF 47Clinical pipeline report, company report or official report of Metabasis Therapeutics (2006).
REF 48Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033866)
REF 49Clinical pipeline report, company report or official report of Inovio.
REF 50ClinicalTrials.gov (NCT01478178) Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma. U.S. National Institutes of Health.
REF 51Antitumor properties of 2(1H)-pyrimidinone riboside (zebularine) and its fluorinated analogues. J Med Chem. 1991 Nov;34(11):3280-4.
REF 52ClinicalTrials.gov (NCT00003021) Bizelesin in Treating Patients With Advanced Cancer. U.S. National Institutes of Health.
REF 53Phase I study of DABIS maleate given once every 3 weeks. Eur J Cancer. 1991;27(12):1635-7.
REF 54Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004610)
REF 55Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002476)
REF 56ClinicalTrials.gov (NCT01648764) A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread. U.S. National Institutes of Health.
REF 57Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors. Clin Cancer Res. 2011 Sep 15;17(18):6071-82.
REF 58ClinicalTrials.gov (NCT01405885) A Study of DNA Vaccine With Electroporation for the Prevention of Disease Caused by H1 and H5 Influenza Virus. U.S. National Institutes of Health.
REF 59ClinicalTrials.gov (NCT01999491) A Phase 1 Dose-Escalation and Pharmacokinetic Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma. U.S. National Institutes of Health.
REF 60ClinicalTrials.gov (NCT00002946) Penclomedine in Treating Patients With Solid Tumors or Lymphoma. U.S. National Institutes of Health.
REF 61ClinicalTrials.gov (NCT00775424) PENNVAX-B With or Without IL-12 or IL-15 as a DNA Vaccine for HIV Infection. U.S. National Institutes of Health.
REF 62ClinicalTrials.gov (NCT01260727) Evaluating the Safety of and Immune Response to an HIV Vaccine Followed by Booster, Administered by Two Devices, in HIV-Uninfected Adults. U.S. National Institutes ofHealth.
REF 63Dissecting the role of multiple reductases in bioactivation and cytotoxicity of the antitumor agent RH1
REF 64Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014468)
REF 65ClinicalTrials.gov (NCT01139151) 4'-Thio-araC (Thiarabine) in Advanced Hematologic Malignancies. U.S. National Institutes of Health.
REF 66Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004282)
REF 67Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002474)
REF 68Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000874)
REF 69Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017581)
REF 70Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007244)
REF 71Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003889)
REF 72Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001664)
REF 73Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36.
REF 74Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005106)
REF 75Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003110)
REF 76Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001279)
REF 77Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015071)
REF 78Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011175)
REF 79Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000815)
REF 80Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018371)
REF 81Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002473)
REF 82Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016219)
REF 83Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011907)
REF 84Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003155)
REF 85Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004376)
REF 86Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004913)
REF 87Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007194)
REF 88Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
REF 89Gene expression analysis of HCT116 colon tumor-derived cells treated with the polyamine analog PG-11047. Cancer Genomics Proteomics. 2009 May-Jun;6(3):161-75.
REF 90Carbonate and carbamate derivatives of 4-demethylpenclomedine as novel anticancer agents. Cancer Chemother Pharmacol. 2009 September; 64(4): 829-835.
REF 91Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
REF 92The ChEMBL database in 2017.
REF 93Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013 Jun;71(6):1645-55.
REF 94Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response. Haematologica. 2011 May;96(5):687-95.
REF 95Effect of 1,2:5,6-dianhydrogalactitol and 1,2:5,6-dianhydro-3,4-diacetylgalactitol on DNA synthesis in the cells of melanoma B16, bone marrow, small intestine epithelium, spleen and liver of mice. Biull Eksp Biol Med. 1984 Sep;98(9):301-3.
REF 96Is the measurement of thymidylate synthase to determine suitability for treatment with 5-fluoropyrimidines ready for prime time. Clin Cancer Res. 2003 Apr;9(4):1235-9.
REF 97Mapping of DNA alkylation sites induced by adozelesin and bizelesin in human cells by ligation-mediated polymerase chain reaction. Biochemistry. 1994 May 17;33(19):6024-30.
REF 98Ambazone as a membrane active antitumor drug. Biophys Chem. 1990 Apr;35(2-3):287-300.
REF 99Alternative DNA loops regulate the arabinose operon in Escherichia coli. Proc Natl Acad Sci U S A. 1988 Aug;85(15):5444-8.
REF 100A novel 9-aza-anthrapyrazole effective against human prostatic carcinoma xenografts. Oncology. 2001;61(3):234-42.
REF 101Single-Nucleotide Polymorphisms in Rv2629 Are Specific for Mycobacterium tuberculosis Genotypes Beijing and Ghana but Not Associated with Rifampin Resistance . J Clin Microbiol. 2009 January; 47(1): 223-226.
REF 102Pharmacokinetics and disposition in the rat of a DNA intercalator 502U83. Drug Metab Dispos. 1993 Jan-Feb;21(1):62-70.
REF 103Sequence selectivity of DNA alkylation by adozelesin and carzelesin. Arch Pharm Res. 1998 Aug;21(4):385-90.
REF 104A new O6-alkylguanine-DNA alkyltransferase inhibitor associated with a nitrosourea (cystemustine) validates a strategy of melanoma-targeted therapy in murine B16 and human-resistant M4Beu melanoma xenograft models. J Pharmacol Exp Ther. 2008 Jul;326(1):171-7.
REF 105DNA damage and sequence specificity of DNA binding of the new anti-cancer agent 1,4-bis(2'-chloroethyl)-1,4-diazabicyclo-[2.2.1] heptane dimaleate (Dabis maleate)Broggini M1, Hartley JA, Mattes WB, Ponti M, Kohn KW, D'Incalci M.Author information1Laboratory of Cancer Chemotherapy, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.Erratum inBr J Cancer 1990 Jul;62(1):172. AbstractThe DNA damage and the sequence specificity of guanine-N7 alkylation produced by the novel, positively charged, antineoplastic agent 1,4-bis(2'-chloroethyl)-1,4-diazabicyclo-[2.2.1] heptane dimaleate (Dabis maleate) and its uncharged tertiary amine analogue 1,4-bis(2'-chloroethyl)-1,4-diazacyclohexane (Dabis analogue) were investigated in L1210 cells and isolated DNA. Both compounds are cytotoxic in vitro causing an arrest of L1210 cells in G2/M phase of the cell cycle. In isolated DNA, Dabis maleate alkylates guanine at the N7-position with some differences in specificity compared to other alkylating agents (e.g. nitrogen mustard). Significant differences are also evident between Dabis maleate and Dabis analogue, suggesting that Dabis analogue is not the sole alkylating species of Dabis maleate. Using the alkaline elution technique a moderate number of DNA interstrand cross-links were detected in L1210 cells treated with both compounds, which were completely repaired within 24 h. Dabis maleate and Dabis analogue do not cause DNA single strand breaks or DNA protein cross-links at the doses at which DNA interstrand cross-links were detected.PMID: 2393411 [PubMed - indexed for MEDLINE] PMCID: PMC1971404 Free PMC ArticleSharePublication Types, MeSH Terms, SubstancesPublication TypesResearch Support, Non-U.S. Gov'tMeSH TermsAnimalsAntineoplastic Agents/pharmacology*Base SequenceBicycloCompounds/pharmacology*Bicyclo Compounds, Heterocyclic*Bridged Compounds/pharmacology*Cell Survival/drug effectsDNA Damage*DNA, Neoplasm/drug effects*Dose-Response Relationship, DrugHumansInterphase/drug effectsLeukemia L1210/pathologyTumor Cells, Cultured/drug effectsSubstancesAntineoplastic AgentsBicyclo CompoundsBicyclo Compounds, HeterocyclicBridged CompoundsDNA, Neoplasm1,4-bis(2'-chloroethyl)-1,4-diazabicyclo(2.2.1)heptaneLinkOut - more resourcesFull Text SourcesEurope PubMed CentralPubMed CentralPubMed Central CanadaOther Literature SourcesCOS Scholar UniverseAccess more work from the authors - ResearchGateMiscellaneousNCI CPTAC Assay PortalPubMed Commons home Br J Cancer. 1990 Feb;61(2):285-9.
REF 106Biological activities of new anthracyclines containing fluorine, FAD104 and its metabolites. J Antibiot (Tokyo). 1990 May;43(5):556-65.
REF 107The heterocyclic ruthenium(III) complex KP1019 (FFC14A) causes DNA damage and oxidative stress in colorectal tumor cells. Cancer Lett. 2005 Aug 26;226(2):115-21.
REF 108Specific metabolic activation of FK973, a new antitumor antibiotic, in L1210 leukemia cells. Jpn J Pharmacol. 1990 Aug;53(4):463-72.
REF 109KW-2149 (7-N-[2-[gamma-L-glutamylamino]ethyldithioethyl] mitomycin C): DNA interactions and drug uptake following serum activation. Biochem Pharmacol. 1998 Jun 1;55(11):1777-83.
REF 110The power and potential of doxorubicin-DNA adducts. IUBMB Life. 2005 Feb;57(2):73-81.
REF 111Phase I study of temozolomide and laromustine (VNP40101M) in patients with relapsed or refractory leukemia. Clin Lymphoma Myeloma Leuk. 2010 Jun;10(3):211-6.
REF 112Novel Cox-2 Inhibitor for Breast Cancer Therapy. Temple University School of Medicine Philadelphia, Pennsylvania 19140. July 2004.
REF 113National Cancer Institute Drug Dictionary (drug id 751473).
REF 114Cell death and DNA fragmentation induced by liposomal platinum(II) complex, L-NDDP in A2780 and A2780/PDD cells. Anticancer Res. 1994 Mar-Apr;14(2A):421-6.
REF 115Use of KW-2189, a DNA minor groove-binding agent, in patients with hepatocellular carcinoma: a north central cancer treatment group (NCCTG) phase II clinical trial. J Gastrointest Cancer. 2007;38(1):10-4.
REF 116The new platinum(IV) derivative LA-12 shows stronger inhibitory effect on Hsp90 function compared to cisplatin. Mol Cancer. 2010 Jun 15;9:147.
REF 117Detection of hypoxia by measurement of DNA damage in individual cells from spheroids and murine tumours exposed to bioreductive drugs. II. RSU 1069.. Br J Cancer. 1995 March; 71(3): 537-542.
REF 118Induction of cyclin E and inhibition of DNA synthesis by the novel acronycine derivative S23906-1 precede the irreversible arrest of tumor cells in S phase leading to apoptosis. Mol Pharmacol. 2001 Dec;60(6):1383-91.
REF 119Site-specific cleavage of RNA and DNA by complementary DNA--bleomycin A5 conjugates. Bioconjug Chem. 2003 Nov-Dec;14(6):1307-13.
REF 120A phase I dose-escalation study of SR271425, an intravenously dosed thioxanthone analog, administered weekly in patients with refractory solid tumors. Am J Clin Oncol. 2009 Feb;32(1):9-14.
REF 121Effects of SW 33377, SW 68210 and SW 71425 thioxanthones on in vitro colony formation of freshly explanted human tumor cells. Invest New Drugs. 1998-1999;16(3):221-5.
REF 122Differential cytotoxicity, uptake and DNA binding of tetraplatin and analogous isomers in sensitive and resistant cancer cell lines. Anticancer Drugs. 1993 Apr;4(2):251-8.
REF 123Troxacitabine. Bull Cancer. 2004 Mar;91(3):213-8.
REF 124Induction of apoptosis by the ADEPT agent ZD2767: comparison with the classical nitrogen mustard chlorambucil and a monofunctional ZD2767 analogue. Br J Cancer. 2001 September; 85(5): 764-771.
REF 125Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2248-54.
REF 126DNA sequence recognition by bispyrazinonaphthalimides antitumor agents. Biochemistry. 2003 Oct 14;42(40):11751-61.
REF 127The comet assay: a sensitive genotoxicity test for the detection of DNA damage and repair. Methods Mol Biol. 2006;314:275-86.
REF 128Cellular pharmacology of gemcitabine. Ann Oncol. 2006 May;17 Suppl 5:v7-12.
REF 129Dicycloplatin, a novel platinum analog in chemotherapy: synthesis of chinese pre-clinical and clinical profile and emerging mechanistic studies. Anticancer Res. 2014 Jan;34(1):455-63.
REF 130Lurbinectedin (PM01183), a new DNA minor groove binder, inhibits growth of orthotopic primary graft of cisplatin-resistant epithelial ovarian cancer. Clin Cancer Res. 2012 Oct 1;18(19):5399-411.
REF 131DNA binding properties of the indolocarbazole antitumor drug NB-506. Anticancer Drug Des. 2001 Apr-Jun;16(2-3):99-107.
REF 132Effects of Treatment with Platinum Azidothymidine and Azidothymidine on Telomerase Activity and Bcl-2 Concentration in Hepatocellular Carcinoma- Induced Rats. Avicenna J Med Biotechnol. 2014 Oct-Dec;6(4): 200-209.
REF 133Complete regression of xenografted human carcinomas by camptothecin analogue-carboxymethyl dextran conjugate (T-0128). Cancer Res. 2000 Jun 1;60(11):2988-95.
REF 134Enzymology of Purine and Pyrimidine Antimetabolites Used in the Treatment of Cancer. Chem Rev. 2009 July; 109(7): 2880-2893.
REF 135Clinical pipeline report, company report or official report of CTI BioPharma.
REF 1366-[Bis(2-chloroethyl)amino]-6-deoxygalactopyranose hydrochloride (C6-galactose mustard), a new alkylating agent with reduced bone marrow toxicity. Cancer Res. 1987 Feb 1;47(3):696-9.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.